Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D06TKR
|
|||
Drug Name |
CART 19
|
|||
Drug Type |
CAR T Cell Therapy
|
|||
Indication | Acute lymphoblastic leukaemia [ICD-11: 2A85; ICD-10: C85.1, C88.7] | Phase 2 | [1], [2] | |
Pancreatic cancer [ICD-11: 2C10] | Preclinical | [3] | ||
Company |
University of Pennsylvania
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | B-lymphocyte surface antigen B4 (CD19) | Target Info | CAR-T-Cell-Therapy | [1], [2], [3] |
KEGG Pathway | PI3K-Akt signaling pathway | |||
Hematopoietic cell lineage | ||||
B cell receptor signaling pathway | ||||
Epstein-Barr virus infection | ||||
Primary immunodeficiency | ||||
NetPath Pathway | IL-7 Signaling Pathway | |||
Panther Pathway | B cell activation | |||
Pathway Interaction Database | BCR signaling pathway | |||
Reactome | PIP3 activates AKT signaling | |||
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | ||||
Constitutive Signaling by Aberrant PI3K in Cancer | ||||
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | ||||
WikiPathways | Human Complement System | |||
Signaling by the B Cell Receptor (BCR) | ||||
PIP3 activates AKT signaling | ||||
B Cell Receptor Signaling Pathway | ||||
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT02935543) CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL | |||
REF 2 | ClinicalTrials.gov (NCT02906371) Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome | |||
REF 3 | ClinicalTrials.gov (NCT02640209) Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL) |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.